Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Rheumatology Patients & Providers Push for Step Therapy, Workforce Changes

Kelly Tyrrell  |  September 20, 2019

Rheumatology professional and patients visited with 117 legislators and their staffs during the 2019 Advocates for Arthritis event to champion better rheumatology patient care and access.

Filed under:Legislation & Advocacy Tagged with:Advocacy 101Advocates for ArthritisRheumPAC

RheumPAC Advocates for Dept. of Defense Arthritis Research Funding

From the College  |  September 17, 2019

RheumPAC is the ACR’s non-partisan political action committee, which promotes the needs of rheumatology providers and patients. Advocacy efforts often focus on legislation to improve the day-to-day clinical care of rheumatology patients, such as establishing clinical exceptions to step therapy requirements and reforming the prior authorization process. In addition, the ACR and RheumPAC recognize the…

Filed under:From the CollegeLegislation & AdvocacyOsteoarthritis and Bone Disorders Tagged with:DoD research fundingResearch FundingRheumPAC

Summer 2019’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel  |  September 17, 2019

Betty Diamond, MD, Recognized as Distinguished Fellow by American Association of Immunologists At its annual meeting in May in San Diego, the American Association of Immunologists (AAI) recognized Betty Diamond, MD, as a distinguished fellow. Dr. Diamond is professor and head of the Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases at the Feinstein Institutes for…

Filed under:AwardsProfiles Tagged with:Dr. Betty DiamondDr. Eric L. MattesonDr. Jinoos YazdanyMovers & Shakers

New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine

Vanessa Caceres  |  September 17, 2019

Hydroxychloroquine (HCQ) therapy may effectively manage systemic lupus erythematosus (SLE) in many patients, but that doesn’t mean patients will take it as often as they should. In fact, results from a recently published study found that about half of SLE patients were not adherent.1 The study was led by Lucy H. Liu, MD, MPH, a…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:adherenceHydroxychloroquine (HCQ)

Case Report: Diagnosing, Treating Hepatitis B-Linked Polyarteritis Nodosa

Naveen Raj, DO, & Lisa Duncan, MD   |  September 17, 2019

Hepatitis B virus (HBV) associated polyarteritis nodosa (PAN) is an increasingly rare vasculitis in developed countries due to advances in HBV vaccination and antiviral therapy. However, the condition does persist, and rheumatologists should consider it when evaluating vasculitis cases. Below, we discuss a case that illustrates the varied clinical presentations PAN can encompass. A high…

Filed under:ConditionsVasculitis Tagged with:case reporthepatitis Bpolyarteritis nodosa

Stealing Time

Philip Seo, MD, MHS  |  September 17, 2019

I knew I shouldn’t look. I was driving 60 miles per hour, heading north on I-95, trying to get to the George Washington Bridge before dusk. It takes a certain fatalism to drive through New York City if you are not a native. Ninety percent of the drivers sharing the road with you know exactly…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:burnoutpatient-centered care

If It’s Broken, Fix It: Can an Automated System Predict Short-Term Fracture Risk?

Jason Liebowitz, MD, FACR  |  September 17, 2019

A clinician’s ability to determine which patients are at greatest risk for hip or other fracture is improving with the use of algorithm-based fracture risk calculators…

Filed under:ConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:EULARfracture riskfracture risk evaluation modelFracturesOsteoporosisTechnology

FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)

Michele B. Kaufman, PharmD, BCGP  |  September 16, 2019

Hadlima (adalimumab-bwwd), which is biosimilar to adalimumab, is now FDA approved to treat multiple autoimmune diseases…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumab-bwwdFDAFDA approvalHadlimaU.S. Food and Drug Administration (FDA)

High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost

Anne Harding  |  September 9, 2019

NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows. “The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabOsteoporosisosteoporosis treatmentsteriparatideteriparatide treatment for osteoporosis

No Gain with Pain: Exercise & Physical Function in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  September 9, 2019

Pain can deter patients with rheumatic disease from engaging in physical activity. But the latest research shows exercise helps reduce pain, & other influences may also affect patients’ activity levels, particularly after surgery…

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:EULARExercisePainPain Managementphysical activity

  • « Previous Page
  • 1
  • …
  • 115
  • 116
  • 117
  • 118
  • 119
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences